Alnylam Pharmaceuticals, Inc. (FRA:DUL)

Germany flag Germany · Delayed Price · Currency is EUR
391.80
-5.40 (-1.36%)
Last updated: Dec 5, 2025, 7:55 PM CET
64.41%
Market Cap 52.72B
Revenue (ttm) 2.74B
Net Income (ttm) 37.13M
Shares Out n/a
EPS (ttm) 0.28
PE Ratio 1,419.78
Forward PE 43.03
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 15
Open 396.50
Previous Close 397.20
Day's Range 391.80 - 396.50
52-Week Range 198.70 - 423.00
Beta n/a
RSI 54.22
Earnings Date Feb 20, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2002
Employees 2,230
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DUL
Full Company Profile

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.